We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+15.6%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$8.4B
AUM Growth
+$1.66B
Cap. Flow
+$1.33B
Cap. Flow %
15.85%
Top 10 Hldgs %
61.33%
Holding
510
New
182
Increased
113
Reduced
52
Closed
146

Top Buys

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$79.7M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$74.4M
3
KVUE icon
Kenvue
KVUE
+$65.3M
4
ELF icon
e.l.f. Beauty
ELF
+$51.7M
5
GSK icon
GSK
GSK
+$46.6M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$96.3M
2
EXAS
Exact Sciences
EXAS
+$56.4M
3
PTCT icon
PTC Therapeutics
PTCT
+$34.5M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$28M
5
MDB icon
MongoDB
MDB
+$23M

Sector Composition

Rank Sector Weight
1 Healthcare 32.56%
2 Technology 5.44%
3 Consumer Discretionary 5.13%
4 Consumer Staples 2.69%
5 Communication Services 1.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DDS icon
401
Dillards
DDS
$9.56B
– –
-898
Closed -$552K
DKNG icon
402
PUT
DraftKings
DKNG
$11.9B
– –
-100,000
Closed -$3.74M
DLR icon
403
Digital Realty Trust
DLR
$71.7B
– –
-1,768
Closed -$306K
DOV icon
404
Dover
DOV
$28.4B
– –
-1,758
Closed -$293K
DRMA icon
405
Dermata Therapeutics
DRMA
$4.42M
– –
-81,654
Closed -$410K
DVA icon
406
DaVita
DVA
$11.7B
– –
-2,157
Closed -$287K
EMN icon
407
Eastman Chemical
EMN
$8.42B
– –
-14,530
Closed -$916K
EQIX icon
408
Equinix
EQIX
$103B
– –
-366
Closed -$287K
EQR icon
409
Equity Residential
EQR
$25.1B
– –
-5,120
Closed -$331K
ESAB icon
410
ESAB
ESAB
$5.71B
– –
-2,719
Closed -$304K
EXAS
411
DELISTED
Exact Sciences
EXAS
– –
-1,030,465
Closed -$56.4M
FCNCA icon
412
First Citizens BancShares
FCNCA
$25.3B
– –
-169
Closed -$302K
FG icon
413
F&G Annuities & Life
FG
$3.67B
– –
-22,541
Closed -$705K
FIVE icon
414
Five Below
FIVE
$13.5B
– –
-2,576
Closed -$399K
FLR icon
415
Fluor
FLR
$7.96B
– –
-6,708
Closed -$282K
FLS icon
416
Flowserve
FLS
$10.2B
– –
-4,461
Closed -$237K
FMC icon
417
FMC
FMC
$1.33B
– –
-6,077
Closed -$204K
FRHC icon
418
Freedom Holding
FRHC
$9.49B
– –
-2,650
Closed -$456K
G icon
419
Genpact
G
$5.81B
– –
-6,708
Closed -$281K
GBDC icon
420
Golub Capital BDC
GBDC
$3.42B
– –
-13,692
Closed -$187K
GIS icon
421
General Mills
GIS
$19.7B
– –
-30,537
Closed -$1.54M
GOVX icon
422
GeoVax Labs
GOVX
$4.01M
– –
-21,356
Closed -$253K
HOG icon
423
Harley-Davidson
HOG
$2.71B
– –
-12,991
Closed -$362K
HPE icon
424
Hewlett Packard
HPE
$70.5B
– –
-9,611
Closed -$236K
HRI icon
425
Herc Holdings
HRI
$5.61B
– –
-2,837
Closed -$331K
15 16
17
18 19

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return
ACM
Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return
PI
PGGM Investments Zeist, Netherlands $5.7B AUM 17.05% 1-Year Est. Return

Armistice Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Armistice Capital held 510 positions worth $8.4B, up 25% from $6.74B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Armistice Capital deployed $1.33B of net new capital in Q4 2025, opening 182 new positions and adding to 113 existing holdings. Its largest new stake was Kenvue: 3,992,196 shares worth $68.9M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 32% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $96.3M trimmed.

  • Armistice Capital's largest Q4 2025 buy was Kenvue: 3,992,196 shares worth $68.9M.
  • Armistice Capital added most to Agios Pharmaceuticals in Q4 2025, an estimated $79.7M increase.
  • Armistice Capital's biggest Q4 2025 reduction was Travere Therapeutics, cutting an estimated $96.3M.
  • Armistice Capital fully exited Exact Sciences in Q4 2025, selling an estimated $56.4M.
  • Armistice Capital's ten largest holdings make up 61% of its $8.4B portfolio in Q4 2025.
  • Armistice Capital opened 182 new positions and closed 146 in Q4 2025.
  • Armistice Capital's portfolio value rose 25% quarter-over-quarter to $8.4B.

Based on Armistice Capital's 13F filing for Q4 2025, filed 17 Feb 2026.